Phapros Tbk PT (PEHA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Phapros Tbk PT (PEHA) has a cash flow conversion efficiency ratio of 0.094x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp41.13 Billion ≈ $2.41 Million USD) by net assets (Rp438.24 Billion ≈ $25.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PEHA market cap overview for the company's overall valuation and market capitalisation.
Phapros Tbk PT - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Phapros Tbk PT's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Phapros Tbk PT Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Phapros Tbk PT ranked by their cash flow conversion efficiency. Explore PEHA cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grand Baoxin Auto Group Limited
F:6BA
|
-0.007x |
|
Petrolympic Ltd
V:PCQ
|
0.013x |
|
Lifestyle Global Enterprise
TWO:8066
|
0.102x |
|
Sparc Technologies Ltd
AU:SPN
|
-0.290x |
|
Global Surfaces Limited
NSE:GSLSU
|
0.033x |
|
CEKD Bhd
KLSE:0238
|
0.024x |
|
High Peak Royalties Ltd
AU:HPR
|
-0.016x |
|
US Copper Corp
V:USCU
|
-0.153x |
Annual Cash Flow Conversion Efficiency for Phapros Tbk PT (2011–2025)
The table below shows the annual cash flow conversion efficiency of Phapros Tbk PT from 2011 to 2025. View PEHA live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Rp427.47 Billion ≈ $25.05 Million |
Rp70.98 Billion ≈ $4.16 Million |
0.166x | -53.79% |
| 2024-12-31 | Rp393.12 Billion ≈ $23.04 Million |
Rp141.28 Billion ≈ $8.28 Million |
0.359x | +2016.64% |
| 2023-12-31 | Rp770.33 Billion ≈ $45.14 Million |
Rp-14.44 Billion ≈ $-846.35K |
-0.019x | -151.56% |
| 2022-12-31 | Rp771.82 Billion ≈ $45.23 Million |
Rp28.07 Billion ≈ $1.64 Million |
0.036x | -85.81% |
| 2021-12-31 | Rp740.98 Billion ≈ $43.42 Million |
Rp189.92 Billion ≈ $11.13 Million |
0.256x | -26.81% |
| 2020-12-31 | Rp740.91 Billion ≈ $43.41 Million |
Rp259.48 Billion ≈ $15.20 Million |
0.350x | +11694.31% |
| 2019-12-31 | Rp821.61 Billion ≈ $48.14 Million |
Rp-2.48 Billion ≈ $-145.42K |
-0.003x | +96.86% |
| 2018-12-31 | Rp789.80 Billion ≈ $46.28 Million |
Rp-75.91 Billion ≈ $-4.45 Million |
-0.096x | -166.07% |
| 2017-12-31 | Rp701.39 Billion ≈ $41.10 Million |
Rp102.03 Billion ≈ $5.98 Million |
0.145x | -20.68% |
| 2016-12-31 | Rp622.08 Billion ≈ $36.45 Million |
Rp114.08 Billion ≈ $6.68 Million |
0.183x | +17.67% |
| 2015-12-31 | Rp449.72 Billion ≈ $26.35 Million |
Rp70.09 Billion ≈ $4.11 Million |
0.156x | -24.29% |
| 2014-12-31 | Rp408.25 Billion ≈ $23.92 Million |
Rp84.04 Billion ≈ $4.92 Million |
0.206x | +313.18% |
| 2013-12-31 | Rp391.40 Billion ≈ $22.93 Million |
Rp19.50 Billion ≈ $1.14 Million |
0.050x | -67.11% |
| 2012-12-31 | Rp375.63 Billion ≈ $22.01 Million |
Rp56.90 Billion ≈ $3.33 Million |
0.151x | +288.78% |
| 2011-12-31 | Rp339.17 Billion ≈ $19.87 Million |
Rp-27.22 Billion ≈ $-1.59 Million |
-0.080x | -- |
About Phapros Tbk PT
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides … Read more